AN 18-MONTH, OPEN-LABEL, SINGLE-ARM SAFETY EXTENSION STUDY OF AN AGE- AND BODYWEIGHT-ADJUSTED ORAL FINERENONE REGIMEN, IN ADDITION TO AN ACEI OR ARB, FOR THE TREATMENT OF CHILDREN AND YOUNG ADULTS FROM 1 TO 18 YEARS OF AGE WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA

Registry ID

20186

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

BAYER INC

Start date

2026-04-22

Last update

2024-04-08

Conditions

• CHRONIC KIDNEY DISEASE (CKD)

Related clinical trials

• A PHASE IIB, RANDOMISED, MULTICENTRE, DOUBLE-BLIND STUDY TO EVALUATE THE EFFECT OF BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH BAXDROSTAT ON ALBUMINURIA IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE (ATTAIN-OUTCOMES)
• A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH AN OPEN-LABEL EXTENSION TO ASSESS THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF EMPAGLIFLOZIN TABLETS IN PAEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE (EMPA-KIDNEY® KIDS)
• A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH DAPAGLIFLOZIN ALONE ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE (BAXDUO-PACIFIC)
• STUDIES OF HEART & KIDNEY PROTECTION WITH BI 690517 IN COMBINATION WITH EMPAGLIFLOZIN: A MULTICENTER, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE ALDOSTERONE SYNTHASE INHIBITOR BI 690517 IN COMBINATION WITH EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MAJOR ADVERSE KIDNEY EVENTS IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN OR EQUAL TO 27 KG/M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE

View on source registry